142 related articles for article (PubMed ID: 28484276)
1. Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.
Kazantseva M; Hung NA; Mehta S; Roth I; Eiholzer R; Rich AM; Seo B; Baird MA; Braithwaite AW; Slatter TL
Sci Rep; 2017 May; 7(1):1566. PubMed ID: 28484276
[TBL] [Abstract][Full Text] [Related]
2. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
[TBL] [Abstract][Full Text] [Related]
4. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?
Asmar F; Hother C; Kulosman G; Treppendahl MB; Nielsen HM; Ralfkiaer U; Pedersen A; Møller MB; Ralfkiaer E; de Nully Brown P; Grønbæk K
Oncotarget; 2014 Apr; 5(7):1912-25. PubMed ID: 24722400
[TBL] [Abstract][Full Text] [Related]
6. [Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma].
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN
Mol Biol (Mosk); 2017; 51(1):64-72. PubMed ID: 28251968
[TBL] [Abstract][Full Text] [Related]
7. Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
Li Q; Huang J; Ou Y; Li Y; Wu Y
Immunotherapy; 2019 Mar; 11(4):265-272. PubMed ID: 30606076
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
Young KH; Weisenburger DD; Dave BJ; Smith L; Sanger W; Iqbal J; Campo E; Delabie J; Gascoyne RD; Ott G; Rimsza L; Müller-Hermelink HK; Jaffe ES; Rosenwald A; Staudt LM; Chan WC; Greiner TC
Blood; 2007 Dec; 110(13):4396-405. PubMed ID: 17881637
[TBL] [Abstract][Full Text] [Related]
9. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
10. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
[No Abstract] [Full Text] [Related]
11. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.
Ebid OAEH; Ezz El Arab LR; Saad AS; Ezz El Din M; Mostafa N; Swellam M
Ann Hematol; 2023 Dec; 102(12):3477-3488. PubMed ID: 37658234
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.
Zainuddin N; Berglund M; Wanders A; Ren ZP; Amini RM; Lindell M; Kanduri M; Roos G; Rosenquist R; Enblad G
Leuk Res; 2009 Jan; 33(1):60-6. PubMed ID: 18706692
[TBL] [Abstract][Full Text] [Related]
13. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
[TBL] [Abstract][Full Text] [Related]
14. BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients.
Akay OM; Aras BD; Isiksoy S; Toprak C; Mutlu FS; Artan S; Oner U; Gulbas Z
Cancer Genet; 2014 Mar; 207(3):87-93. PubMed ID: 24674866
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma.
Kimura M; Yamaguchi M; Nakamura S; Imai H; Ueno S; Ogawa S; Miyazaki K; Oka K; Ohno T; Kita K; Kobayashi T; Shiku H
Int J Hematol; 2007 Jan; 85(1):41-8. PubMed ID: 17261501
[TBL] [Abstract][Full Text] [Related]
17. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
Davies AJ; Lee AM; Taylor C; Clear AJ; Goff LK; Iqbal S; Cuthbert-Heavens D; Calaminici M; Norton AJ; Lister TA; Fitzgibbon J
Leukemia; 2005 Aug; 19(8):1459-65. PubMed ID: 15902285
[TBL] [Abstract][Full Text] [Related]
18. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
20. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
